Login
BeyondSpring Inc. logo

BeyondSpring Inc.

beyondspringpharma.com

What Do They Do?

Develops Plinabulin and other potential cancer medicines for patients, and works with pharmaceutical companies on drug discovery through its SEED subsidiary.

Who Are Their Customers?

Pharmaceutical companies collaborate with BeyondSpring on drug discovery and product development. Hospitals and investigators conduct Plinabulin studies with the company's financial support and drug supply.

How Are They Changing?

Since the FY2025 annual report
  • Sep 30, 2026 Sold subsidiary that indirectly held interests in Bulin The investor will conduct the China portion of the Plinabulin trial in exchange, and BeyondSpring retains access to the clinical data.
  • Jun 4, 2026 CEO transitioned and new CEO and CFO were appointed Lan Huang remained Chair; Min Qiu became CEO and Na Li became CFO.

SEED adds a partner and clinical candidate The older report described SEED's protein-degradation work with Eli Lilly; the latest report also names Eisai and says SEED's wholly owned cancer candidate has advanced into clinical studies.

Who Do They Compete With?

Competes with Bristol-Myers Squibb, Merck &, and Eli Lilly

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support